Lancaster General Hospital

Running trials

• Not yet recruiting

  MyStroke for Stroke Survivors and Caregivers

  NCT06442631· Source

• Recruiting

  A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)

  NCT07361510· Phase 3· Source

• Recruiting

  ELEVATE-HFpEF Clinical Study

  NCT06678841· Source

• Active, not recruiting

  ASCEND CSP IDE Study

  NCT06830746· Source

• Recruiting

  Dilated Cardiomyopathy Detection Using AI and Screening With Mobile Technology (DCM-DETECT)

  NCT06688396· Source

• Active, not recruiting

  The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

  NCT06383390· Phase 3· Source

• Active, not recruiting

  Assessment of Combined CCM and ICD Device in HFrEF

  NCT05855135· Source

• Active, not recruiting

  Left Atrial Appendage Exclusion for Prophylactic Stroke Reduction Trial

  NCT05478304· Source

• Enrolling by invitation

  An Extension Study to Assess Long-Term Safety of Eplontersen in Adults With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)

  NCT05667493· Phase 3· Source

• Recruiting

  Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

  NCT05174169· Phase 2/3· Source

• Active, not recruiting

  Peer Comparison Feedback to Providers to Improve Hypertension Control

  NCT05160012· Source

• Active, not recruiting

  Cardiotoxicity in Locally Advanced Lung Cancer Patients Treated With Chemoradiation Therapy

  NCT04305613· Source

• Recruiting

  A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer

  NCT04251052· Source

• Active, not recruiting

  Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to the Usual Radiation Treatment for Newly Diagnosed Early Stage High Intermediate Risk Endometrial Cancer

  NCT04214067· Phase 3· Source

• Active, not recruiting

  Adjuvant Treatment Determined By Pathological Response To Neoadjvuant Nivolumab

  NCT04013854· Phase 2· Source

• Active, not recruiting

  Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer

  NCT03914612· Phase 3· Source

• Active, not recruiting

  Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC)

  NCT03811002· Phase 3· Source

• Active, not recruiting

  Ipilumumab and Nivolumab With or Without Hypofractionated Radiotherapy in Patients With Metastatic Melanoma

  NCT03646617· Phase 2· Source

• Active, not recruiting

  A Study to Compare Zolbetuximab (IMAB362) and Chemotherapy With Placebo and Chemotherapy in Adults With Gastric Cancer.

  NCT03504397· Phase 3· Source

• Recruiting

  Real-world Experience of Catheter Ablation for the Treatment of Arrhythmias

  NCT04088071· Source

• Active, not recruiting

  Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

  NCT02839707· Phase 2/3· Source

• Active, not recruiting

  Maintenance Chemotherapy With or Without Local Consolidative Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer

  NCT03137771· Phase 2· Source

• Active, not recruiting

  Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

  NCT02446600· Phase 3· Source

• Active, not recruiting

  Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

  NCT02465060· Phase 2· Source

• Active, not recruiting

  Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer

  NCT02488967· Phase 3· Source

• Active, not recruiting

  Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

  NCT02152982· Phase 2/3· Source

• Active, not recruiting

  Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic

  NCT02115282· Phase 3· Source

• Active, not recruiting

  Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

  NCT02048813· Phase 3· Source

• Active, not recruiting

  Erlotinib Hydrochloride and Cabozantinib-s-Malate Alone or in Combination as Second or Third Line Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer

  NCT01708954· Phase 2· Source

• Active, not recruiting

  Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

  NCT01167712· Phase 3· Source

• Active, not recruiting

  Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma

  NCT00644228· Phase 3· Source

• Active, not recruiting

  Lenalidomide and Dexamethasone With or Without Thalidomide in Treating Patients With Multiple Myeloma

  NCT00098475· Phase 3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Heart failure2 recruiting
• Amyloidosis1 recruiting
• Atrial fibrillation1 recruiting
• Lung cancer1 recruiting
• Ovarian cancer1 recruiting
• Stroke1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Terminated

  Parasympathetic Augmentation Via Respiratory Training for Patients With Systolic Heart Failure

  NCT05223751· Source

• Terminated

  Study of Magrolimab Combination Therapy in Patients With Head and Neck Squamous Cell Carcinoma

  NCT04854499· Phase 2· Source

• Completed

  Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma

  NCT04396860· Phase 2/3· Source

• Completed

  CARDIO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Participants With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)

  NCT04136171· Phase 3· Source

• Terminated

  Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer

  NCT03199885· Phase 3· Source

• Completed

  Benefits of µCor in Ambulatory Decompensated Heart Failure

  NCT03476187· Source

• Completed

  Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery

  NCT01950390· Phase 2· Source

• Terminated

  Connect® Myeloid Disease Registry

  NCT01688011· Source

• Completed

  Efficacy of Oral Azacitidine Plus Best Supportive Care as Maintenance Therapy in Subjects With Acute Myeloid Leukemia (AML) in Complete Remission

  NCT01757535· Phase 3· Source

• Completed

  S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery

  NCT01120249· Phase 3· Source

• Completed

  Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery

  NCT00324805· Phase 3· Source

• Completed

  Oxaliplatin, Leucovorin, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer

  NCT00217737· Phase 3· Source

• Completed

  Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer

  NCT00066690· Phase 3· Source

• Completed

  High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma

  NCT00003641· Phase 3· Source